Clinical Trials · NCT01910194

Impact of Combined of Lantus(Insulin Glargine) and Lyxumia (Lixisenatide) on Insulin Secretion and Gastric Emptying

CompletedPhase 2Lixisenatide (Approved)
Phase
Phase 2
Recruitment status
Completed
Sponsor
Profil Institut für Stoffwechselforschung GmbH
Enrollment
39
Start date
Dec 2013
Locations
2 sites, Germany
Primary endpoint
AUCISEC(0-10min)
View Lixisenatide compound reference